throbber
(SAZ-Bd ZAA1 - l'oN'St '1o1'nunadotaqlpuo tSolocowtotld lDrtullJlo tDuno1lDuotloutaluy
`
`s3t tuEu{poceuJeLld puP sctlou tloceuleL{d
`oL.ll Jol onrp Mou e .uBtu ut outpoloilol lo
`l{1rnrlceJono Joppplq fueurJn lo luotuleoll
`
`zqNn'I9QH
`
`'d'rdql/'l-IYd ''I'raunrog :O'd 6rN$'I'IVH'8'.rHvr5 'S'hl'I I 'riINNIug'N
`gNOSSlsIusvC 'f puP
`' o7o s dd 11' gy ur4o td 2 T Dt rDw n)q d' {3 o 1o corutorq 4 ytctutl 3 lo ruaw n d a qi
`' pun"1 to l'o11 d s o 11 {1t s t a uu 2' tB o 1o cotutotq 4 loctutl 3 lo ruawu o d a q,
`' Lulot4yrots' gy uqo td p T otrDlurDq d' Ltlstwaqcor g 1on1cnt1g to tuatulnda g,
`puo' olos dd p' gy uqo td p T Dl rowrDtl d' fu lstwaq 3 yt crt(Touoot g lo uou ca g,
`'sruauqo)DutrDqd puD s)rtnarDwrzt1do1g lo uorst^te'{coutnq4lo ruawttodaq,
`uapaws.' o1os dd1' tlts nuu 2 o1os dd I
`
`pue 'scrtueu,{poceuuuqd 'scrlauDlocuruJsqd eq1 euruuelep 01 sem fpnls slql Jo IUIB eqJ 'lJBJlsqv
`frepuoces V'sreelunlo^ fqtpeq ur sesop snouelerlur pu€
`IBJo ey8uts SurmolloJ eulporellot;o f1a;es
`'Z'0 Jo sesop lero e13ur5 'ecuepq ssuru euruuelep pue selqoqeleru .{reuun roluur ,(grluepl ol sB,{\ tuIB
`epu ,(qtpeq 11 o1 ua,,rr8 erem (lps ete$mt aqt se) eulporeUot Jo 3- 8'Zt pue't 9'Z'E'9'I'8'0 't'0
`pue sreelunlo^ eql Jo g ol peJelsrurupe erea (3ru gZ't pue t9'0) sesop snouenerlul o1r\J 'sJeelunlol
`eurpoJelloJ 'slcefqns 9 ur eurpoJellot-(Jy1) 3ur ggo esop Iero e18urs e JaUB perpnls sB^\ ecuBleq ssetu
`'(q y'O + 6'0 uorleJluecuoc turues 4eed o1 erurt) uorlerlsrurupe pro 8uvrro1o; peqJosqe ,(lprdur su,tr
`uorlnqrJlsrpJo eunlo^ eq3-'ob1Lol 0I uro4 Sur8uer'elq?IJe^ ,(g8rq sem fllpqule,reotq elnlosqu eql
`'3ffi1 7g'g ol €Z'O uro4 pe8uer ecueJ€elc crurels,{s pw 8VI 9'I 01 6'0 uror; pe8uer elels-,(puals te
`pue r.usqoq?leru ssed-1srr; qSrq peltqqxe eulporelloJ 'Ll t - Z p eJII-JIuq Ieuluual e ut petlnseJ IIcIq^\
`Jo elnor ;o luepuedepul 'uorle1,$I1eep puu uorl€prxo
`:perJrluepr ererrr s,(uznqled crloqeleu c:0:edeq 7
`eJe,r selrloquler.u elrg 'euun ur pe8ueqcun peleJcxe se,Lr punoduoc luered eql Jo obl > 'uollpJlslulurp€
`Jo uorleJcxe oql 'eurporellof(Jtl) Jo uorleJlsrurupe Iero 3umo11og 'euun uI pelJlluepl(1prnyrru1s
`pes€ercep eurpoJellol '.{lelrlcedser 'obg't + I I pue ob1'V + LL set seceJ pue euun olur flr,ttlcuotpur
`g'ZI ret1a uorsrl Jo lurodreeu pue '3ut V'g reg€ elBJ ilBeq peseercur '?ut Z'E rege uoIlBAIIes pelelntulls
`tceJrp e Jo >Icel eq1 '8ur 8'ZI Jo esop e rege seIlFcIJJIp uolllJntcltu pegoder slcelqns g;o xrg '3ur
`pe1se33ns uorlelrles pelelnrurls uo slceJJe pu€ suorl?Iuecuoc urrues eulpoJeqol uearrrleq drqsuotleler
`'(s)elqoqeleu e,lr1ce,(lecfoloceuueqd ;o ecueserd eql
`"tuoonr"-'"nrlcu - sreelun1o,r. ,{qtpeq - ecueleq sselu - sclleul>locBuu€qd - aurporellol :sproal ,{ay
`
`uollJnporlul
`
`-Jnlsrp olur pepl^Ip eq ,{uru uorlunlcttu Jo srepJoslc
`Jo uo4cunJ 8ur,$dure eql ro uollcunJ e8erols eql Jo secwq
`secrreqJnlsrp;o suroldrufs uIBITI eql 'reppelq freuun eql
`-uocut pue ',{cue8rn '.{cuanber; eJe uollcunJ a8erols eq1;o
`I€uuou
`lBql e^erleq ol suosBeJ eJB eJeql uetu uI 'ecueull
`qlr^\ pelurcosse suorlceJluoc sB IIel( se suollceJluoc Jepp€lq
`crurJecsnru ,(q ,{lureru pelerpeu eru ,tt,r.tlcure^o Jeppulq
`'uoseor srql rod '[9661 uossrepuy] uortepurrls roldecer
`
`' L66I 'U prdy u.uo; pest,t er ut peldaccu :966I 'Zl leqrueto(l pe^receg
`'.(8o1oceuuuq4 1€JrurlJ Jo luetuuedeq'euufrg'p':q ol ecuepuodselro3
`'uepe^\S'epsddn 7 g 1 91- g' gy uqofdn ? €Irulrrreqd
`
`-ep Jo lueruleer JoJ pesn ueuo eJB s8rup cluuecsnlullue
`'r(lrrrrlcere,ro rosn-rl
`-eue sB qcns 'spunoduoc unluoluure ,fteu-re1en|
`-ruor ere 'eprtuoJq eurleqluedord pue eplluoJq urnruord
`esaql'.{lrzr.rlcerelo Jeppulq Jo luoruteer1 eql ut pesn,(potu
`ueq.^A uollcunJ reppelq uo slceJJe pelueuncop e,r.eq s8rup
`-uV pue uelsurn '086I 'Ie le s€^IBIg]
`.{lpreluered ue,r,r8
`lereqdrred'rea,emoH'|LL6I uossrep
`-pe cruu€csnurrlue
`'qlnou,{rp se qcns slceJJe esJe^
`'srs,{1ered uorl€poluruocce
`eseql Jo sseue^IlcoJJe eql pelIuII e,req urprec,tqcel pue
`rood;o esnuceq .ftesseceu uego sr uorlerll esoq 'slua8e
`8ur.r,ro11o3 uorlerru^ IenpIAlpuuelur q8rq pue,{lqrqepuneorq
`'IB te Ipapun5] uorlerlsrururpu IBro
`'[ 1961 'p 1e eso1 '€t6I
`.{pueunc st '8rup peluauncop IIea e sI qcrq.Lr'uru,$nq,(xg
`Jo lueruleeJl eql ur ecroqc Jo 8rup eql eq ol peJeplsuoc
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1007 - Page 1
`
`

`
`288
`
`Brynne, Stahl, Hall4n et al.
`
`patients with bladder overactivity [Yarker et al. 1995]. The
`utility of this agent is restricted by a high incidence of
`adverse effects, such as dryness of the mouth [Cardozo et
`al. 19871.
`No currently available therapeutic agent has a selec-
`tive action on the muscarinic receptors of the bladder. A
`drug with a high antimuscarinic potency and a more blad-
`der-selective action is therefore desired. Preclinical data
`have shown that tolterodine ((R)-N,N-diisopropyl-3-(2-
`hydroxy-5-methylphenyl)-3-phenylpropanamine) exerts a
`high antimuscarinic potency in guinea pig and human
`detrusor muscle [Naerger et al. 7995, Nilvebrant et al'
`19941.It has also been shown that tolterodine displays a
`favorable tissue selectivity for the urinary bladder over
`salivary glands in the anesthetized cat [Gillberg et al.
`19941.
`Preliminary studies in healthy volunteers suggest that
`tolterodine bxerts a marked inhibitory effect on micturition
`fStahl et al. 1995]. The objective ofthe present study was
`to determine the pharmacokinetics, pharmacodynamics,
`and safety of tolterodine following single oral and intrave-
`nous (i.v.) doses in healthy volunteers. A secondary aim
`was to identify major urinary metabolites of tolterodine
`following oral administration and to quantify urinaryfecal
`excretion (mass balance).
`
`Subjects, material and methods
`
`Study drugs
`Tolterodine is a weak base (pKa 9.9) with an oc-
`tanol/phosphate buffer partition coefficient (log D) at room
`temperature of 1.8 at pH 7.3 (data on file lPharmacia &
`Upjohn ABI). For the purposes of this study, tolterodine
`(as the tarlrate salt) was prepared as water solutions (150
`ml) for use in dose escalation studies while a solution of
`1laC)-tolterodine (labelled in the u-posirion, 957o radio-
`chemical purity), together with unlabelled tolterodine, was
`prepared for determination of mass balance. Oral solutions
`of tolterodine were prepared by the Pharmacy, Lund Uni-
`versity Hospital, Sweden, while i.v. solutions of
`tolterodine were prepared by Pharmacia and Upjohn AB,
`Stockholm, Sweden.
`
`Subjects
`
`A total of 23 male Caucasian volunteers were in-
`cluded in the 3 parts ofthe study (oral dose escalation, i.v.
`administration, and mass balance determination). All vol-
`unteers were judged to be healthy by clinical examination,
`electrocardiography, and evaluation of laboratory parame-
`ters prior to study enrolment. Seventeen volunteers partici-
`pated in the oral dose escalation studies. Their mean (+
`standard deviation, SD) demographic characteristics were:
`age 28 + 7 years, body weight 77 ! 10 kg, and height 1.8 I
`
`I 0.04 m. Eight of these subjects subsequently received
`tolterodine i.v., while 6 additional volunteers received
`(14C)-tolterodine orally for determination of mass balance.
`The mean (t SD) demographic characteristics of these 6
`volunteers were: age 45 + 6 years, body weight 15 X 4kg,
`and height 1.80 I 0.06 m. Each participant provided in-
`formed written consent and the study protocol was ap-
`proved by the Ethics Committee of the University of Lund,
`Sweden.
`
`Study design
`
`The subjects fasted ovemight (from l0 p.m.) before
`drug administration and they abstained from food until a
`standardized lunch was given (4 h after drug administra-
`tion). No other drugs were allowed for 2 weeks prior to and
`48 h after each administration. In addition, smoking and
`the consumption of alcohol and caffeine-containing bever-
`ages were restricted prior to and for 48 h after drug intake.
`In the dose escalation part of the study, tolterodine
`was given as a single oral dose of 0.2,0.4,0.8, 1.6, 3.2,6.4,
`or 12.8 mg. Two subjects per dose were included in the
`lower dose interval (0.2 - 1.6 mg), while 8 subjects re-
`ceived 3.2, 6.4 and 12.8 mg, respectively. Blood samples
`( l0 ml) were drawn into Vacutainer tubes without additives
`prior to and at 0.33, 0.66, 1, 2, 3, 4, 6, 8, and 24 h after drug
`administration. After coagulation at room temperature for
`approximately 0.5 - I h the blood samples were centrifuged
`(1,000 g for 10 min). Serum was immediately separated,
`fuozen, and stored at -20o C pending analysis. Urine was
`collected quantitatively O - 24 h and 24 - 48 h after
`tolterodine dosage. Heart rate and blood pressure (supine)
`were simultaneously recorded by an automatic, noninva-
`sive, digital blood pressure meter (UA-751 , A and D Com-
`pany Ltd, Japan). Nearpoint of vision was determined
`using a RAF nearpoint rule (Clement Clarke Ltd., UK).
`Stimulated salivation was measured with a slightly modi-
`fied method used by Dollery et al. fl9761. The subjects
`chewed I tablet of paraffin (Orion Diagnostica, Espoo,
`Finland) altemately on the left and right side of the mouth
`for 5 min. All saliva was carefully collected in a plastic cup
`and weighed in order to calculate salivation flow (g/5 min).
`Measurement of heart rate, blood pressure, nearpoint of
`vision and stimulated salivation were performed prior to
`and at 0.25, 0.15, 1.25, 1.15,2.25,2.15,3.25,3.75, 4.15,
`5.25, 5.7 5, 6.25, 6 ;7 5, 1 .25, and 7 ;7 5 h after the administra-
`tion oftolterodine.
`Eight ofthe 17 subjects included in the dose escalation
`also received tolterodine i.v. Two subjects received a 5-min
`infusion of tolterodine 0.64 mg while all 8 subjects re-
`ceived an i.v. infusion of tolterodine 1.28 mg over 10 min.
`Blood samples (10 ml) were drawn prior to and immedi-
`ately after the infusion, and at 0.33, 0.66, 1, 2,3, 4,6,8,
`and 24 h after completion of the infusion. Quantitative
`collection of urine and measurement of heart rate, blood
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1007 - Page 2
`
`

`
`Qd puo xd aulporalloJ
`
`682
`
`uorlelrles pelelnurls pue 'uorsrl go lurodrueu 'ernsserd
`'e^oqe peqrJcsep w peuuo3.red ererrr
`ssetu eql ur pepnlcu ere,tr slcelqns 9 l€uorlrppu uV
`3u E e18urs B pe^receJ lcelqns qceg 'uorp8rlselur ecu€luq
`seldues I€red
`'eurporetlol-(Jrr) Jo esop pro (r3rl 911)
`s,(ep 1 roJ sle^relu q, VZ q fler'r1e1r1uenb petcelloc ere^\
`- 8V'gV - VZ'VZ- 8 '8 - t'y - g s1e,ue1ur eqt ur euun pu€
`8rup rege Lt B9t - WI pue' WI - OU' 0U - 96'96 - Z L' ZL
`-gpuepr roJ pesn (qVZ - g) seldues euFl l 'uorl€Jtsrururpe
`- S'€ Hd o1 pelsnlpe erelrr selqoqeleru eurporellolJo uortec
`tuelerd ot prce crqJocse W S'0 ul tOSzH I tr Z qll,\\ 0't
`seldruus pceJ pue euun 'runJes IIV 'sessecoJd erlrleprxo
`'srs.{1eue tpun 3 "02-N
`uezo4 perols ere,^a
`-eJ eJel( sluala esJelpe pegoder r(lsnoeuuluods 1y
`peuruuelep urc8u ere.Lr sreleurered '{.ro1uroqe1
`pue pepJoc
`'pue ,{pn1s le sreolunlol IIe roJ
`
`atnpato.td 1ot!I[|DuV
`
`eJeA\ euun puB unJes ur suorlBJluecuoc eurpoJelloJ
`',(rleurorlceds sseur/,{qderSoletuorr{c se8 Sursn peuruuelep
`,(ruurrn 'pJupuels Ieruelur eql sB enSoluuu pelerelnep e qlr,tr
`3urmo11o; passesse oslu eJe,rr eurpoJellol Jo suorl€Jluecuoc
`re8uuqeog) esepruorncnlS-d Wt^ seldures Jo uorteqncur
`-puets Ieruelul sll pue eurporelloJ '(.{ueuueg 'urrequuepl
`purcrpep Jo tueruuudeq eqt ,(q pezrseqlu,{s eJea pJs
`-e,rs 'ruloq>lcols 'gV uqofdn pue urJuuuurl4',{4srrueq3
`pesrls{le Jo lurz- I ruo4 pelceJlxe ere,Lr se1,(pue eqJ 'uep
`6 : 1) reqte 1,(q1erp/euelued pr g olur eldures (lt * t t Hd)
`ur 'sseufrp o1 eseqd cruu8ro eql Jo uorlurodu.r,e .regy '(,t/,r
`0g qlll\ pezrle^rrep se,r enprser eql 'ue8orilu Jo ruuers e
`'(epnueleceorongrrl-(1,(ps1'(qteurur)-srq-O'N) VCJSS Ili
`urunloc,{repdec zclys pesnJ e uo pelerrlce se,t uorleredeg
`Sursn '(urd Eg'g 'ruur ZZ'0 - ur gZ 'Z ro 1 er11n 411)
`qlr. a peuuoJJed se,Lr uorlcele6l'Suruure:3ord ernleredruel
`pelmeg) rolcelep e^rtceles sseru qSIN IL6g to 0t6g dH ue
`ere,r L8E 4w pve ZBE zlur suor eqJ '(ygn 'p-ru1ce4
`slr pue eurporellol;o Suuolruotu uor-e13urs roJ pesncoJ
`Ieuelur
`perederd selrnc pmpu€ls',{le,r.r1cedser'prepuels
`er.IJ 'VFd 0g - g'0 e8uer eqt urqil.r,r rdeurl eJe^\ rurues ur
`JoJ uorlerJe^ .{eprelur eqJ 'll3rl S'0 sB,^A uortcetep Jo tlu4l
`sezvr /8ri Z'LV - 6'l e8uer uorle4uocuoc orp uI ourporollol
`'oblllpuu 00I ueealeq peue,r.{Serncce eqtpve obL>
`peruroped ereztr,fi r,,r.rlceorpeJ lulol Jo sluetueJnseenl
`ererrr seldureS 'eurrn prm uorlnlos IsJo eql 3o slonbrle ur
`,$1,r.r1ceorper pue (VSn 'pre1ce4) ploC eunlln qtr,^A petnlp
`eueque3) ,ftteurortceds uouellrlurcs pmbq ,{q pernseeu
`pazrueSoruoq arez'r seldrues pceg '(ygn '00S2 UJ pJDIO?d
`ere,tr slonbrle pue Qq8re,u IBceJ eql setu11 t - g) relem ur
`Iepo4 rezrpxo eldueg prelce4) pelsnquoJ prre perrp
`flluenbesqns se,tr flr,rrlceolpe5 '(VSn 'tgE
`ur perns€eru
`-eilrlurcs pmbl ,(q (ygn 'pre1ce4) rongeu;e4,/qrosoqreJ
`',(rleuorlceds uorl
`elrlJeqruv uo pelceJlxe eJea selrloqeleur freuun
`Iou€qleu qtr^\ peuonlpuoo 'urru 08I x tI) Z-CVX
`pu€
`
`-eJ Jepun peleJluecuoc pue 'lou€qleru qlr. a petnle '(re1e,u
`-uoIlcBU ere,4A selrloqeleu luereJJrp eq;'ernsserd pecnp
`,{qderSoleruorqc prnbq esuqd-pesre.r.er e,rrlerederd,{q pele
`8IJ {ed e,top ud 9 qll.^.\ pe>lced urunloc 1e6 der4 e uo
`ere,tr se1,(yuuu eqJ' (V Sn'yy,q'e;odrp6 srep16) selcrged
`eAIloBoIpBJ eql puu relel\ ur luerper8 loueqleu e qlr.^A petnle
`e^rlceorped 'palPJluecuoc puB pelcelloc eJe,4A suorlce4
`-pesreleJ pcrfpue uB uo perJund requn; erea suorlre4
`pFbII SVd-llrC fq pez(letrc .{11eurg pue urunloc eseqd
`-e1eu pele8nluocun',ftleurorlceds sseru/qderSoleruoJqc
`-erSoleruorqc su8 fq pez[1uue puu pete1,(ps ere,^d, selrloq
`'uorluSruor lcudrur uor1cele q1,l .{rleurorlceds sseurT,(qd
`
`srsQouo r4oq
`
`ereq,Lr ldecxe 'cs + u?etu se pesserdxe er€ ulep ilv
`-sn peuuoJJed su,Lr srs,(pue plueugedurocuoN'polecrpur
`-BJlsrulrupu rulnJs€^er1xe nJ (Z'V uorsre,r) urpo5134 3ur
`erll ropun BerB eqJ '[9961 sluullnsuo3 I€Jrtsrtets] uort
`.reeuq ,{q peurelqo se,lt, elJnc eurl-uorleluecuoc turues
`qty( [286i relued pu€ 1ppqlD] uorteurxordde leprozederl
`elep pelrrperd 1se1 eql Surpr,r.rp fq flrur;ur o1 uorlulodurlxe
`qVZ - Z eqt ruo4 pe,nFep) z1 'edols luuruuel eqr .{q lurod
`-qe eleldruoc Sununssu '(S/fC) ecuereelJ prg '(p.tre1ur
`-ce pelepclec ere,\\ (Z/It) oJrf-Jleq IeuruJet pue 'uorldros
`'[9661 rezol pue puel,4d,oU] spoqleur pJepuels o1 Surproc
`Iepou pnueuodxerq e 'srs,(pue uorsserSer oql uI
`[7961 rerue4 pue rpleqrg] (Z prrc t suorlenbe)
`pellrJ s€.t\
`ur) elep uorlerluecuoc rurues IpJo pup ',t'r o1 ,{lsnoeu€llnturs
`Jo eleurlse Jelleq B le8 ol puu Iepou eql ezrlrqels ol ropro
`:(,(1r1rqeye,r,eorq
`
`[",-" (,'.."-') fJ=,'ft= "''
`
`(r)
`
`k) . [,r-"
`
`1#*,",, " L#]?"r*a;= "',
`eql seuoceq puu uorsnJur eql Surrnp 1 sr e ereq,^A
`eql Jo uouessec reue (uorsn;ur;o uorlernp) Jull luelsuoc
`'uorsnJur
`roJ pepnlcw eq ol pepoou (8rtt) erult-8e1 e 'flereueg
`1see1 pelq8rem ,(q epp eqt ol peurJ se,r Iepou eqJ '€tup
`IeJo
`'cpcrcll rolcug Surlq8re,r eql Sursn uorsser8er se:enbs
`Jo (AJ) uorl€u€l
`Jo luercrJJeoc eqf teqt seunsse qcrq,{
`eqJ 'luelsuoc se,4d sluerueJnseeu uorleluecuoc eql uo JoIIe
`erJelrJJ IeJeAes o1 lcedser qll.lA eperu se,r Iepou Jo ecroqc
`plueuruedxe 01 slepotu eql Jo trJ Jo sseupooS eql ssosse ol
`'uorlJunJ alrlceiqo eqt :slYrolloJ se eJea BrJeluo esoql'plep
`;o uorsrcerd eql pus'spnprser eqt;o lold eqlJo renecs eql
`elels-,{puels lB uollnqulsrp Jo eunlo^ eq1 '.releurered qcee
`oJII-JI€q uorldrosqe'(13) ecuereelc ruluos cruelsfs'(Ssn)
`(fUl$ eturl eoueprsor u€oru pue (g) ,{111rqe1re,reorq'(ezllt)
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1007 - Page 3
`
`

`
`290
`
`Brynne, Stahl, Hall4n et al,
`
`TableI pertinentkineticestimatesobtainedaftersimultaneousfitoforaldata(3.2,6.4,arfi12.8mg)andinfusiondata(1.28mg)afteradministration
`of tolterodine to healthy volunteers.
`
`Parameter
`
`C*u* (pgA)
`t *(h)
`F (Vo)
`Vss G/kg)
`cL (l/h&e)
`MRr (h)
`trpp G)
`cLlF (l/h/kg)c
`
`Mean
`
`6.2u
`0.gu
`43
`1.4
`0.36
`4.1
`3.2
`1.6d
`
`3.2ms.h=4)
`Range
`
`CY (Va)
`
`54ms(n=3)
`Range
`
`cv (sa)
`
`Mean
`
`12.8 ms (n = 5)
`Range
`
`cv (qo)
`
`<0.7 - 13
`0.7 - 1.0
`23 -74
`0.9 - 1.6
`0.24-0.46
`2.9 - 6.7
`2.4 - 52
`0.38 - 3.1
`
`74
`t9
`51
`25
`2l
`44
`41
`63
`
`g.6b
`
`0.9b
`34
`1.4
`0.37
`4.2
`J.J
`2.4b
`
`2.5 - l7
`0.7 - 1.5
`23-48
`1.1 - 1.6
`0.23 - 0.47
`2.8 -7.0
`2.3 -5.3
`0.56 - 5.4
`
`63
`33
`38
`l8
`34
`57
`51
`83
`
`25b
`1.1b
`33
`1.3
`0.43
`3.0
`2.4
`l.7b
`
`56
`53
`55
`13
`
`6.8 - 54
`o.3 -2.0
`10-60
`1.1 - 1.4
`0.32 - 0.52 18
`2.7 - 4
`2.t - 2.9
`\ 0.71 - 4.8
`
`9.3
`13
`76
`
`a=basedonTsubjects,b=basedon8subjects,'=estimatedbynoncompartmentalanalysis,d=basedon6subjects,C.u*=peakserumconcentration'
`tmu = time to Cmu, F = bioavailability, Vs5 = volume of distribution at steady-state, CL = systemic semm clearance, MRT
`mean residence time,
`trpp = elimination half-life, cLA = oral clearance, cv = coefficient of variation
`
`1
`
`Fig. I Serum concentration time
`profiles of tolterodine after 6.4 mg
`oral (panel A) and 1.28 mg intrave-
`nous (panel B) single-dose admini-
`stration of tolterodine to 8 healthy
`volunteers.
`
`6b
`_10
`.E
`
`Eeoocoorl
`
`?oo
`
`bc
`
`.9
`
`10
`
`EcogboE
`
`Poo
`
`1
`
`were estimated according to standard equations [Gibaldi
`and Perrier 19821.
`Radioactivity in urine and feces was deterrnined quan-
`titatively and described as a function of time.
`
`Results
`
`AII subiects complied with the study protocol and
`completed the trial. Since only 2 subjects per dose level
`were included for the lower oral doses of 0.2 - 1.6 mg this
`presentation will emphasize the pharmacokinetics and
`pharmacodynamics after tolterodine doses of 3.2,6.4' and
`12.8 mg (8 volunteers per group).
`
`Pharmacokinetics
`
`Pharmacokinetic parameters from the noncompart-
`mental analysis and the simultaneous fit to oral and i.v. data
`are presented in Table 1 and serum concentration time
`
`profiles after 6.4 mg oral and 1.28 mg i.v. administration
`in Figure 1. Tolterodine was rapidly absorbed at all dose
`levels, time to peak serum levels (tmax) following oral
`administration was 0.8 - 1.1 h. A proportional increase in
`mean peak serum concentration (Cma*) (6.2 - 25 Fg/l) was
`observed at doses of 3.2 - 12.8 mg. CLiF showed high
`interindividual variability (range 0.38 - 5.4 Uh/r;g without
`any obvious dose relationship. Mean 1172 was constant (2.5
`- 3.0 h) with increasing dose. After a mean thg of 0.3 t 0.3
`h, tolterodine was absorbed withal'/;aof 0.4 + 0.3 h. The
`initial distribution phase was rapid (1.1tz11 < 0.33 h).
`Bioavailability exhibited high variability between indi-
`viduals, ranging from 10 to 74%o,while V55 and CL ranged
`from 0.9 to l.6lkg and from 0.23 to 052lhkg, respec-
`tively. On the basis of these results, MRT and elimination
`half-life (trlzp) were estimated to be 3 - 7 h and 2 - 3 h,
`respectively. Renal excretion of unchanged tolterodine was
`< l7o duringthe first 48 h and was independent of dose and
`route of administration. Similarresults were obtained when
`urine samples were incubated with B-glucuronidase prior
`to analysis.
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1007 - Page 4
`
`

`
`cld puD xd autporaqoJ
`
`T6Z
`
`+
`
`-oqeteu freurrn per;Duepl Z'3ll
`go esop pro 8ur g e13urs e rege salq
`-un1ol dqlpeq w eutporeqo1-(30,)
`pue) setlloqBletu IIV
`'sreel
`se perJpuepl osle ere^\ (eulporellol
`-(Jor) Jo uoPlsod eq1 'sePruomcnlS
`eqt u! (*) peluclpur sr 3uq1eqe1
`'elnJelour eulpoJellol
`
`astloqqaw puD aJuDlDq ssDw
`
`Io obS'Z+V6'uorle4srunupe 8rup uro4 s,(ep 1uqtt16
`-loceJ se,4d peJelslurrupe fll,rrlceotper;o lunorue plol eql
`-cedser'secoJ pue eulrn uI obg'E+ LIplur- obO'V+ 27)pale
`pelercxe serrr (o63'9 aP7) fltnlceorper 6qt;o lsoyq'(,{1e16
`'q tz ulqll^\ seceJ plrs euun uI
`ur perJrluepl sellloqBlelu eulporellol Jo seJnlcn4s erlJ
`q8noqllv '7 ern8rg ut u.{\oqs ere seldulus euun q VZ- 0 eql
`-eq peu?^ sellloqelelu 3I{l Jo suollurluecuoc e^Ilsler eql
`prru (€AD elqoqulelu prce cq,(xoqrec eq1 'slcefqns ueel$
`-uoc ere.{\ (qn1) etqoqetetu plc? cq,(xoqrec pelelAlpep aql
`-eue saldues ile ur sellToq€letu
`lueuluoperd eql ,(1luelsts
`Jo obLI + 08 JoJ pelunocc? sellloqsle(u 7, J€nq eql 'pez,(I
`+ 6Z'q\l'obO'VI + IS 'BAI) f1,r'rlceorper ^{reuFn 1e1o1
`pelunoccs eJe/|,qrrrrlceorpet 1o o5gT?urulslueJ eqJ' Qt"o' g
`sll qtp\ 3uo1e (e1) elfloqeletu pe1e1.(xorpfq eqt .{q rol
`pep1,(4uep'eulporellol 1cu1ur'(q11) ru-ro; pep1,t41eep
`-urus Ieced 'seleSnluoc epruorncnlS 4eql pue eulpoJellol
`uorlueleJ relrtuls qlr.tr sellToqeleru roleru 7 peurcluoc seld
`qtrm lued ou ellqa 'sellloqeteuI qAI pue €AI eql ol selull
`
`eurporellol lcelul Jo leql o1 Sutpuodseuoc eurll uollueler B
`'pe^Jesqo se.t\
`
`scttuoutpocowrDl'ld
`uo 3ru 8'ZI pue 'V'9 'Z'E eulporellot Jo speJJe eI{J
`-€Arles pelelnurls puu 'uoISIA Jo lurodreeu 'eler u€eq uuatu
`qlr^\ pelplcosse sE^\ eulpoJello;'g ern8rC ur u.&\oqs eJe uoll
`qcrq,^A Jo lesuo eql'e13r il€eq uI eseercur luepuedep-esop e
`- g'I punoJu lceJJe I€uIxBIu 01 erull qltn prder ,{ptu; se.u
`ur pe^Jesqo elBJ u€eq uI eseeJcul un{uIXBIu eq.L 'q 8'I
`g + 6I ss,r\ 3.u 8'Zt eulpoJallol pe^Iecer oLIl( sreelunlo^
`Jo sesop lE pepeJJ€
`lou set\ uoISI^ Jo lurod:ee51 'uru/spoq
`-uu^ Ienpr^rpuuelul elqereplsuoc q8noqtp '?ut V'9 pue Z'E
`urru ZEJo eseeJcul uaelu?'lserluoc uI'lueredde su,$ flrTrqe
`luersuel e Surmolog '3* 8'Zt Jo esop €
`le palJesqo s€A\
`llnseJ E se ,{lqeqord tsoru) uo4e,il1es pelslnIulls uI es?orJul
`-nlos IBJo re11rq f11q31ys eql pue 'Fu 009 'e>IBluI relu^\ Jo
`er{J 'pelJesqo su,{a l*rog fw,rqes uI eseercep prder e '(uo4
`€' I UqUA\ peUIBllE sB/!\,^(\ou,{re,'rt1es ur esueJJep umIuIxBLu
`tsotule ue 8ur 8'ZI rc pue uollsrslulrup€ 3rup rege q 8'I -
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1007 - Page 5
`
`

`
`II
`
`TI
`
`Brynne, Stahl, Hall4n et al.
`
`Flg. 3 Mean (t SEM) heart rate
`(panel A), nearpoint of vision (panel
`B) and stimulated salivation (panel
`C) time profiles after single oral
`doses of tolterodine 3.2 mg (trian-
`gles),6.4 mg (squares) and 12.8 mg
`(circles) in healthy volunteers (8
`subjects in each dose group).
`
`292
`
`A
`9Or
`
`C5
`
`so
`T;70
`Et
`Eoo
`I
`
`50
`
`300
`
`9,*.e(tt
`t2@
`c'3,*
`6oz
`
`100
`
`15
`
`€a
`
`10o
`.EEE6o
`
`complete inhibition of stimulated salivation was achieved.
`No clinically significant changes in either systolic or dia-
`stolic blood pressure were seen in any subject.
`
`C o nc e ntr ation-r e sp ons e r e lations hip
`
`The heart rate and salivation responses paralleled the
`tolterodine serum concentration time curves, peak re-
`sponses were observed around tmax &Ild declined with the
`elimination of tolterodine. There was a slight delay be-
`tween serum concentrations and heart rate response, but no
`apparent hysteresis for the effect on stimulated salivation.
`In Figure 4 the relationship between effects on heart rate
`and stimulated salivation versus serum concentrations of
`
`tolterodine has therefore been illustrated by a logJinear
`regression line (slope 2.5 (based on salivation data)). The
`Figure illustrates the lack of selectivity between the 2
`measured effects. However, a considerable difference in
`the maximal degree of the responses was seen. Maximal
`changes in heart rate and stimulated salivation observed
`after 12.8 mg were about+30Vo md-90Vo, respectively, of
`the pre-dose value. Figure 5 shows the salivary response
`versus serum concentrations after oral and i.v. administra-
`tion of tolterodine. Although comparable serum tolterodine
`concentrations were achieved after oral and i.v. administra-
`tion, only small decreases in stimulated salivation were
`observed after i.v. infusion compared with the oral route.
`Figures 4 and5 are based on observation up to 4 hours after
`dose.
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1007 - Page 6
`
`

`
`od puo xd aulporalloJ
`
`t6z
`
`9L
`
`oo
`
`od
`. Vt
`fv
`rr v
`
`3=
`
`(t
`(o
`=.o5
`
`0,
`
`z
`
`3f
`
`aOI
`otg'r.
`
`9r
`C"
`
`99Go!, € oL 3.
`
`go
`
`I osg
`
`99
`
`0s
`
`0t
`
`(ilOrl) uolerpecuoc urrues
`
`(s1oqru,(s pellrJ) uonp^rtps pue (qoqru,(s uedo) e1e: geeq weyl p'?tg
`sesop pro e18urs rolJ€ eurpoJellolJo uolelueJuor {urues sns:el esuodse:
`leql eloN '(selilrr) 3ru g'71 pue (serenbs) 3ru y 9 '(se13uura) 3u 7'g go
`'pennuo uoeq seq Surproco: uortelrps urur gI oql
`
`&11tqota7o1
`
`eql Surrnp pegoder eJea sluele esJelpe eJeles oN
`'(lluenber; lsour eq; '.{pn1s
`eJe,^A sluele esre^ps pegoder
`' ?tu g' Zt'slce lqns L'Srrr V' g' slce lqns g' ?vt Z' ) qlnoru,(rp
`g'7 1'nefqns t'?ut V' I serllnJrJJrp uorlunlcnu'(slcelqns g
`g '8ur 8'ZI) uorluporuruocce peqJntsrp '(slcelqns 9 '3ur
`-qns 7 '3ur g'71) suelqord purtselurorlse8 puu (slcefqns
`reue q 9I o1 dn ro; pelsrsred serllnJrJJrp uorlrnlcrl4l'(slcel
`sno^reu IBIuec o51 '8ru 8'ZI eurporellol Jo uorlur1srurtup€
`ur se8ueqc luecr;ru8rs ,{1pcru11c ro slcoJJo esrolpe uels.(s
`',{pn1s eqt Suunp pelou eJelvr sreleurersd froleroqel
`
`uolssnJSlo
`
`;o .{1r1qepe,,'eorq elnlosqu eqt turltt Surpug eq1
`(olrVL ot 0I ruo4 Sur8uu:) elq€rru^
`,{g8rq surn eurpoJellol
`sezlr Snrp eql lBrll Jeqlre pe,^ or{s esop Jo luapuedepur pue
`o1 pelqns s€^\ eurporellol wql ro 'paqJosqu fleleldruocur
`ue,tr8 eql Io obLL ecurs 'uorleururqe crurels,(serd
`-c€orp€J
`sr uorlfuosqe pro qSrq B 'euun ur peloJcxa se,ld esop elrl
`Y?ruJ pu€ prdur sem eurpoJellolJo uorldrosqe eq1'pe11drur
`3urlse38ns uorlersrurupe Snrp yo rI I u1qll.,tA peqceeJ sB.^
`'eurlsolur llsurs eql ur ,{1ureu permcco uorld:osqe eql legl
`eql Jo uorlces srql q8norql eurl lrsuer e8erele eq1 eJurs
`eqJ '[996I '1e 1e serrreq] q € punoru sr lcu1 IeurlselurorlseS
`selucrpw (ZS't C 3o1) eurporellot roJ tuerrrJJeoc uorlrued
`-ueru pcrSolorq ssoJce ,(ppuer ssed pm 8rup eql tzql
`eq ol ruedde lou plp leql ssecord B 'seueJq
`ecurs 'elq€Jnl€s
`elep eseqt '.Ilere^O '(t etqeD luelsuoc peumureJ diTJ
`-rJe^ pue elrsuelxe seoSrepun eurporellol rcW petseSSns
`
`0r_
`(n
`
`0t
`
`fu6rl) uorge.lluocuoc uInJaS
`
`Jo uorp.DueJuoJ rrnues sns.re,L esuodseJ uorlulrl€s uee1,1 g 3lg
`pelpy) 3ur 7'9'(sey8uuurpelp3) 3ru Z'EJo sosop Iero o18urs:ege eurpo:eqo1
`gz I Jo uorsnJur ',r'r e18urs e rsge pue (selrrb pellrJ) 8ru g'zt pue (serenbs
`IBJo urru-gI eql teql eloN'sreetrm1o,t,{qtpeq ur (seycnc uedo) 8ru
`-Blrl€s
`'penrruo ueeq seq 8up:ocer uon
`
`eleldruocur ueql reqlur 'rusrloq€leru ssed-1srrg crledeq eyqe
`'uorldrosqe
`> Jo nzlq e qU.,rA petnqrrlsrp ,(yprder s€,rvr eurporelloJ
`6'0 ruo4 pe8uer SsA'(uru S punoJ€ sesec tsoru ur) unu 97
`,(1elr1e1er eqlqlr.ry\ tuerueer8e le.reue8 ur sl qc1{r!\ '3VI 9'I ol
`eseq;'punoduoc eqlJo scrlsuelrereqc crlqdodrl elerepour
`ur peur€rueJ punodruoc luered eql Jo obg > teqt fldrur etep
`eurpoJellol l€r{l pue 'elels-fp?els lB uorlulncrrc cruelsf s eq1
`'seueJqueu enssrl selerleued
`arqt lo ob1L 'eurpore11o1-(Jy1) Jo uortelsrunupe roUV
`fpeerp ,{lieuer peleJcxe se,tr flr,rrlceorpeJ Jo esop lelol
`Jo rusrloqeletu eql rcqt ,uoqs s8urpur; eseqJ 'q VZ urrlttw
`eurporellol So dzltl 'ssecord prdur ,(yrre; e se,^a eurporellol
`7 q8norql se^\ rusqoqeleu ,fierurrd oqJ 'q t - Z sew
`rolpue dnorS 1,(q1eu-g eqt go uorlzprxo :s.(unqled tuereggrp
`-etu prc€ cr1,{c,{xoqruc o.4A1 eqJ '(1 ern8rg) uone1,{4pep-111
`o699 tptr-utrxordde ro; pelunocce 'qAI pue eAI '.setqoqel
`'euun ur peJeloceJ flr,rrlceorpur eq1 ;o
`ol tZ'0 uror; pe8uur eurpoJellol Jo ecueJuelc cnuels,(g
`s€^\ esop perelsrurupe eqt lo obI > 'reAe.4AoH 'AilWt ZS'O
`-pe Jo elnoJ;o e,Lrlcedseur 'euun ur peStreqcun peleJcxe
`-rJru8rs elnqrluoc lou plp uorlorcxo ,fuelllg 'uorlz4sruru
`s?^\ 8rup eql ecurs eurporellol Jo uorlEurrurle eql ol .{lluec
`-oq leql polseSSns sSurpurJ eseqJ'seceJ ur olq€lcolep
`lou
`lBrll pu? uorlEurrurle Jo elnor uretu eql sr usqoqsleru ciled
`€ Sururnssv 'eleldtuoc lsorup sr eurporellol Jo rusrloqeleu
`crledeq e pue ,{lrun Jo orl€J uorleJluecuoc IUrues
`: poolq
`Jo uortcsrtxe crlsdaq eql 'urufi 9'I Jo ,4doll poolq
`eql 'Je^eaoH 'ob\, - 0z Jo eSuuJ eql ur s31v\ eurpoJellol
`
`Petitioner Mylan Pharmaceuticals Inc. - Exhibit 1007 - Page 7
`
`

`
`294
`
`Brynne, Stahl, Hall4n et al.
`
`estimated bioavailability (10 - 707o) cleatly suggested
`variable first-pass elimination, which may reflect differ-
`ences between subjects with respect to metabolic capacity.
`The systemic clearance of subject 1 6 (0.23 lkkg was thus
`notably lower than the overall average, and h2p of
`tolterodine in this subject was considerably longer (5'3 h).
`This dissimilarity was probably due to differences in he-
`patic metabolic capacity. Recently, Stahl et al. [1995]
`reported a subject with atr2gof 15 h following a single 6.4
`mg oral dose of tolterodine. The metabolic phenotype of
`this subject was subsequently characterized, using
`mephenytoin and debrisoquine - two probe drugs that are
`well established for determination of the polymorphically
`distributed cytochromes P450 2Cl9 and P450 2D6
`(CYP2CI9 and CYP2D6) [Bertilsson 1995]. The subject
`was classified as an extensive metabolizer of mephenytoin
`and a poor metabolizer of debrisoquine, which indicates
`that CYP2D6 may be involved in the metabolic clearance
`of tolterodine.
`Since it is difficult to obtain consecutive response
`measurements on the bladder over time, we assessed
`known antimuscarinic effects - such as increases in heart
`rate and nearpoint of vision and decrease in stimulated
`salivation - in order to characterize the pharmacological
`effects of tolterodine. While the absence of a placebo group
`in this study limited the interpretation of the effects of
`tolterodine, overall trends could be observed. At a dose of
`12.8 mg the maximum increase in heart rate was 20
`beats/min and an almost total inhibition of stimulated
`salivation occurred. Both responses were superimposable
`and suggest that the concentrations of tolterodine at an
`approximate half maximal response, on heart rate and
`salivation, were about 6 - 8 pg/I. The differences in mag-
`nitude might indicate that muscarinic M: receptors in
`glands are more sensitive to blockade than Mz receptors in
`the heart. However, there was an overlap between the
`serum concentrations where the respective responses oc-
`curred, which is in agreement with preclinical findings that
`did not demonstrate selectivity for a single muscarinic
`receptor subtype [Nilvebrant et al. 19961.
`Data from a urodynamic study in healthy volunteers
`by Stahl et al. [1995] showed that a single 6.4 mg oral dose
`of tolterodine exerts a powedul inhibitory effect on mic-
`turition, both subjectively and objectively. The reported
`rapid onset of an effect on the bladder is in agreement with
`the pharmacokinetic data in this study. Stahl and colleagues
`concluded that a dose of 6.4 mg would be too high for use
`in a future patient population. No effect on accommodation
`for nearvision was found at the dose used by Stahl et al.,
`while at a dose of 3.2 mg no apparent effect on hearl rute
`and only a slight inhibition of stimulated salivation was
`found. In contrast to the salivary response, the effect of
`tolterodine on urodynamic parameters did not change
`markedly between 1 and 5 h after drug administration
`lStahl et al. 1995]. The cause of the relatively longer
`duration of the bladder response is at present unclear.
`
`However, data from preclinical studies in the anesthetized
`cat have shown a more shallow dose-response relationship
`for effect on the bladder compared with effect on salivation
`[Gillberg et al. 1994]. If there is a similar dose-response
`relationship in man this might be associated with the sub-
`jective reports of persistent micturition difficulties for up
`to 16 h after drug administration in this study.
`There was a large discrepancy between the observed
`effect and tolterodine serum concentrations after oral and
`i.v. administration. This was evident for decreased saliva-
`tion as well as increased heart rate. This suggested a major
`contribution from an active metabolite(s) besides the phar-
`macological activity of tolterodine. Since the salivation
`response profile closely followed the tolterodine serum
`concentration time curve it seems likel! that the pharma-
`cokinetics of the active metabolite(s) is formation rate-lim-
`ited. The effect on salivation might have a pharmacody-
`namic ICso value at metabolite concentrations correspond-
`ing to 6 - 8 pgA ofparent tolterodine after oral dosage (but
`not after i.v. administration).
`The incidence of adverse effects was less frequent at
`lower doses and typical antimuscarinic adverse effects
`were clearly dose-related up to 12.8 mg. In view of the
`adverse events profile, clinical laboratory and vital signs
`data, tolterodine was judged to be well tolerated at all dose
`levels up to 12.8 mg.
`
`Acknowledgements
`
`We thank Dr. Karl-Erik Andersson and Dr. Bengt Sparf for their
`valuable contributions to the development of these initial human phatma-
`cological studies. We are grateful to R.N. Gertrud Lundquistforher skilful
`assistance.
`
`REFERENCES
`
`Andersson K-E 1993 The pharmacology of lower urinary tract smooth
`muscles and penile erectile tissues. Pharmacol Rev 45: 253-308
`B ertil ss on Z 1995 GeographicaVinterracial differences in polymorphic
`drug oxidation - Current state of knowledge of cytochromes P450
`(CYP) 2D6 and2Cl9. Clin Pharmacokinet29: 192-209
`B laiv as J G, Labib KB, M ic halik J, Zay e d AAH 7980 Cystometric re sponse
`to prophanteline in detrusor hyperreflexia: therapeutic implications.
`I Urol 124: 259-262
`Cardozo LD, Cooper D, Versi E 1981 Oxybutynin chloride in the man-
`agement of idiopathic detrusor instability. Neurourol Urodyn 6:
`256-25'7
`Davies

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket